SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, today reported positive data from a multicenter clinical study (NCT 04708951) comparing the adenoma detection rate (ADR) of its FDA-cleared G-EYE® balloon technology against ENDOCUFF VISION® (ECV) technology in patients undergoing screening or surveillance colonoscopy. Results from this randomized trial, the first head-to-head comparison of these two colonoscopy mechanical enhancement devices, showed that the ADR, particularly for advanced and large adenomas, was higher for the G-EYE® balloon than for the ECV attachment. Seth Gross, MD, Professor, Department of Medicine at NYU Grossman School of Medicine, Clinical Chief, Division of Gastroenterology and Hepatology at NYU Langone Health, and co-author on the abstract, presented the data in an oral session at ACG 2021, which is taking place October 22-27 in Las Vegas (ACG 2021, Presidential Plenary Session 1, Abstract #S233).
Trending
- AI-Assisted Colonoscopy and the Diminutive Adenoma Dilemma (Los Angeles Times)
- BE Surveillance, Outpatient ESD, and More (GI & Endoscopy News)
- HHS-OIG Issues Favorable Advisory Opinion for Free Multi-Cancer Detection Supplemental Reports Provided with Medicare-Covered Colorectal Cancer Screening Tests (The National Law Review)
- Physician–researcher’s work yields landmark five-year data for Crohn’s disease drug (Medical Xpress)
- CU Anschutz Biobank Partners with Tech Company to Advance Gut Research and Patient Care (The Regents of the University of Colorado)
- Novant Health adds leading gastroenterology clinicians to its Lowcountry network (Novant Health)
- Solutions Emerging for Post-GLP-1 Weight Regain (Medscape)
- CMS Grants Medicare Coverage for ColoSense®, Expanding Access to Simplified Noninvasive Colorectal Cancer Screening (Business Wire)
